Analytical Data
-
Gene name
TGFBR3/TGF-beta RIII
- Application
-
Alternative Names
BGCAN; Beta-Glycan; Betaglycan; Proteoglycan
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 97% as determined by SDS-PAGE.
-
Uniprot
P26342
-
Expression Region
Asn210~Ala465
-
Protein Length
Partial
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Transforming growth factor-beta receptor 3 (TGFBR3), also known as the TGF-beta RIII, plays a crucial role in the TGF-beta signaling pathway, which is pivotal for various cellular processes, including proliferation, differentiation, and apoptosis. TGFBR3 acts as a co-receptor that enhances the binding of TGF-beta ligands to their primary receptors, TGFBR1 and TGFBR2, thereby modulating the signal transduction pathways that are essential for maintaining cellular homeostasis. Dysregulation of TGFBR3 has been implicated in numerous pathological conditions, including fibrosis, cancer, and autoimmune diseases, highlighting its potential as a therapeutic target. Recent studies have focused on the generation of recombinant TGFBR3 proteins to investigate their functional roles in these diseases, as well as to explore their utility in therapeutic applications. The recombinant protein can be used to better understand the mechanisms of TGF-beta signaling, and it provides a valuable tool for drug screening and development. Additionally, the ability to produce large quantities of purified TGFBR3 paves the way for potential clinical applications, including the design of targeted therapies aimed at modulating TGF-beta activity in various disease contexts. Research into TGFBR3 continues to evolve, emphasizing its importance as a critical mediator in TGF-beta signaling and its relevance in the development of innovative treatments.
